April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.

The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.

A roundup of the first quarter's key oncology drug approvals and rejections.

A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.